Venclexta (Venetoclax) Patent Expiration, LOE Window & CMS Spending
Venclexta (Venetoclax) by AbbVie: FDA Orange Book core substance LOE 2032-01-29 (last listed 2033-09-06), 1 AB generics, $984.8M 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N208573 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2032-01-29 |
| Last Listed Patent or Exclusivity Date | 2033-09-06 |
| Orange Book Patents (*PED Extensions) | 10 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $984.8M |
| 2024 Medicare Part D Spend | $941.7M |
| 2024 Medicaid Spend | $43.1M |
| Reported Wholesale Price Change (CA SB 17) | 24 WAC filings (max 20.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.